MYL2 and cancer: MLC-2 overexpression reduced cellular traction force, while its downregulation increased cytoskeletal stiffness, traction force, and invasion of PDAC cells through retinoic acid receptor B, a nuclear receptor that, when dysregulated, accompanies the early stages of cancer [21].